Suppr超能文献

溶质载体家族 35 成员 F2 在灵长类血脑屏障三种细胞模型中的功能研究。

Functional Investigation of Solute Carrier Family 35, Member F2, in Three Cellular Models of the Primate Blood-Brain Barrier.

机构信息

Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan (T.Mo., T.Mi., H.K.); Laboratory of Drug Disposition and Pharmacokinetics, Faculty of Pharma-Sciences, Teikyo University, Tokyo, Japan (T.K., K.H., Y.T., Y.D.); Laboratory of Stem Cell Regulation, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan (T.Y., K.K.); and Drug Metabolism and Pharmacokinetics Tsukuba, Tsukuba Research Laboratories, Eisai Co., Ltd., Tsukuba, Ibaraki, Japan (Y.N.).

Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan (T.Mo., T.Mi., H.K.); Laboratory of Drug Disposition and Pharmacokinetics, Faculty of Pharma-Sciences, Teikyo University, Tokyo, Japan (T.K., K.H., Y.T., Y.D.); Laboratory of Stem Cell Regulation, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan (T.Y., K.K.); and Drug Metabolism and Pharmacokinetics Tsukuba, Tsukuba Research Laboratories, Eisai Co., Ltd., Tsukuba, Ibaraki, Japan (Y.N.)

出版信息

Drug Metab Dispos. 2021 Jan;49(1):3-11. doi: 10.1124/dmd.120.000115. Epub 2020 Nov 3.

Abstract

Understanding the mechanisms of drug transport across the blood-brain barrier (BBB) is an important issue for regulating the pharmacokinetics of drugs in the central nervous system. In this study, we focused on solute carrier family 35, member F2 (SLC35F2), whose mRNA is highly expressed in the BBB. SLC35F2 protein was enriched in isolated mouse and monkey brain capillaries relative to brain homogenates and was localized exclusively on the apical membrane of MDCKII cells and brain microvascular endothelial cells (BMECs) differentiated from human induced pluripotent stem cells (hiPS-BMECs). SLC35F2 activity was assessed using its substrate, YM155, and pharmacological experiments revealed SLC35F2 inhibitors, such as famotidine (half-maximal inhibitory concentration, 160 μM). Uptake of YM155 was decreased by famotidine or SLC35F2 knockdown in immortalized human BMECs (human cerebral microvascular endothelial cell/D3 cells). Furthermore, famotidine significantly inhibited the apical (A)-to-basal (B) transport of YM155 in primary cultured monkey BMECs and hiPS-BMECs. Crucially, SLC35F2 knockout diminished the A-to-B transport and intracellular accumulation of YM155 in hiPS-BMECs. By contrast, in studies using an in situ brain perfusion technique, neither deletion of nor famotidine reduced brain uptake of YM155, even though YM155 is a substrate of mouse SLC35F2. YM155 uptake was decreased significantly by losartan and naringin, inhibitors for the organic anion transporting polypeptide (OATP) 1A4. These findings suggest SLC35F2 is a functional transporter in various cellular models of the primate BBB that delivers its substrates to the brain and that its relative importance in the BBB is modified by differences in the expression of OATPs between primates and rodents. SIGNIFICANCE STATEMENT: This study demonstrated that SLC35F2 is a functional drug influx transporter in three different cellular models of the primate blood-brain barrier (i.e., human cerebral microvascular endothelial cell/D3 cells, primary cultured monkey BMECs, and human induced pluripotent stem-BMECs) but has limited roles in mouse brain. SLC35F2 facilitates apical-to-basal transport across the tight cell monolayer. These findings will contribute to the development of improved strategies for targeting drugs to the central nervous system.

摘要

了解药物通过血脑屏障(BBB)的转运机制对于调节中枢神经系统中药物的药代动力学非常重要。在这项研究中,我们专注于溶质载体家族 35,成员 F2(SLC35F2),其 mRNA 在 BBB 中高度表达。SLC35F2 蛋白在分离的小鼠和猴脑毛细血管中相对于脑匀浆富集,并仅定位于 MDCKII 细胞和分化自人诱导多能干细胞(hiPS-BMECs)的脑微血管内皮细胞(BMECs)的顶膜上。使用其底物 YM155 评估 SLC35F2 活性,并且药理学实验揭示了 SLC35F2 抑制剂,例如法莫替丁(半最大抑制浓度,160μM)。在永生化人 BMECs(人脑微血管内皮细胞/D3 细胞)中,法莫替丁或 SLC35F2 敲低降低了 YM155 的摄取。此外,法莫替丁显著抑制了原代培养的猴 BMECs 和 hiPS-BMECs 中 YM155 的顶端(A)到基底(B)转运。至关重要的是,SLC35F2 敲除减少了 hiPS-BMECs 中 YM155 的 A 到 B 转运和细胞内积累。相比之下,在使用原位脑灌注技术的研究中,即使 YM155 是小鼠 SLC35F2 的底物,也没有删除或法莫替丁降低 YM155 的脑摄取。YM155 的摄取显著降低了洛沙坦和柚皮苷,它们是有机阴离子转运蛋白(OATP)1A4 的抑制剂。这些发现表明 SLC35F2 是灵长类动物 BBB 的各种细胞模型中的功能性转运蛋白,将其底物递送至大脑,并且其在 BBB 中的相对重要性通过灵长类动物和啮齿动物之间的 OATP 表达差异而改变。意义陈述:本研究表明,SLC35F2 是灵长类动物血脑屏障(即人脑微血管内皮细胞/D3 细胞、原代培养的猴 BMECs 和人诱导多能干细胞-BMECs)中三种不同细胞模型中的功能性药物内流转运蛋白,但在小鼠脑中的作用有限。SLC35F2 促进紧密细胞单层的顶端到基底转运。这些发现将有助于开发将药物靶向中枢神经系统的改进策略。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验